Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Kevin J Harrington"'
Autor:
Ezra E.W. Cohen, Danny Rischin, Burak Gumuscu, Kevin J. Harrington, Nicolas Mach, Lillian L. Siu, Beatriz Castelo, Anthony Kong, Jason Chesney, Hoi-Shen Radcliffe, Wendy Snyder
Publikováno v:
Journal of Clinical Oncology. 39:6036-6036
6036 Background: T-VEC, a genetically modified herpes simplex virus-1, is the first FDA- and EMA-approved oncolytic viral immunotherapy designed to enhance systemic antitumor immune responses. R/M HNSCC is a disease with considerable clinical complex
Autor:
Tamara Rordorf, Anthony Hee Kong, Jason Chesney, Jenny J. Kim, Jesus Corral Jaime, Vittoria Espeli, Burak Gumuscu, Kevin J. Harrington, Nicolas Mach, Sheryl Treichel
Publikováno v:
Journal of Clinical Oncology. 36:6036-6036
6036Background: We evaluated the safety and efficacy of the combo of T-VEC, the first FDA-approved oncolytic immunotherapy that enhances systemic antitumor immune responses, and Pembro, an immune c...
Autor:
Kevin J. Harrington, Vijayvel Jayaprakash, Li Li, Peter Brossart, Mark Lynch, Robert L. Ferris, Naomi Kiyota, George R. Blumenschein, Jérôme Fayette, Joël Guigay, Maura L. Gillison, Nabil F. Saba, Lisa Licitra
Publikováno v:
Journal of Clinical Oncology. 36:6028-6028
6028Background: Nivo is the only immunotherapy to significantly improve overall survival (OS) in pts with platinum (plt)–refractory R/M SCCHN. In the randomized, open-label, phase 3 CheckMate 141 t...
Autor:
Dimitry Serge Antoine Nuyten, Zelanna Goldberg, Nancy Y. Lee, Margarida Geraldes, J. Thaddeus Beck, Robert I. Haddad, Kevin J. Harrington, Ezra E.W. Cohen, Makoto Tahara, Robert L. Ferris, Jean Bourhis
Publikováno v:
Journal of Clinical Oncology. 35:TPS6093-TPS6093
TPS6093 Background: Cisplatin + radiotherapy is a standard-of-care treatment for patients (pts) with LA SCCHN. Combining avelumab (fully human IgG1 anti–PD-L1 antibody) and CRT may synergistically activate multiple immune-mediated mechanisms to eff
Autor:
Maura L. Gillison, Nabil F. Saba, Caroline Even, Peter Brossart, George R. Blumenschein, Lisa Licitra, Joël Guigay, Jérôme Fayette, Jeffrey Russell, Robert I. Haddad, Robert L. Ferris, Kevin J. Harrington, Shanmugasundaram Ramkumar, Jin Zhu, Manish Monga, Makoto Tahara, A. Dimitrios Colevas, Everett E. Vokes
Publikováno v:
Journal of Clinical Oncology. 35:6020-6020
6020 Background: In CheckMate 141, nivo resulted in significantly prolonged overall survival (OS), favorable safety, and stable quality of life vs IC in patients (pts) with platinum-refractory (PR) R/M SCCHN. Cetuximab, a formal trial stratification
Autor:
Luciano de Souza Viana, Tomoya Yokota, José Dinis, Manuel Chaves-Conde, Chaitali Singh Nangia, Jan B. Vermorken, J.G.M. Segalla, Robert I. Haddad, Ilya Romanov, Jean Bourhis, Jose Manuel Trigo Perez, Kevin J. Harrington, Irina A. Vasilevskaya, E. Ehrnrooth, Amanda Psyrri, Neil W. Gibson, Bushi Wang, Ezra E.W. Cohen, Makoto Tahara, Barbara Burtness
Publikováno v:
Journal of Clinical Oncology. 35:6001-6001
6001 Background: Locally advanced HNSCC is treated curatively, but recurrence is common. In HNSCC, EGFR is richly expressed and EGFR inhibition is validated treatment (tx); the ErbB family blocker afatinib (A) showed efficacy in recurrent/metastatic
Autor:
Jérôme Fayette, Robert L. Ferris, Everett E. Vokes, Kevin J. Harrington, Caroline Even, Maura L. Gillison, Robert I. Haddad, William J. Geese, George R. Blumenschein, Manish Monga, Nabil F. Saba, Lisa Licitra, Fernando Concha-Benavente, Yasuhisa Hasegawa, Makoto Tahara, Chia Jui Yen, Mark Lynch, A. Dimitrios Colevas, Stefan Kasper, Francis P. Worden
Publikováno v:
Journal of Clinical Oncology. 35:5-5
5 Background: Nivolumab, an anti-programmed death-1 (PD-1) monoclonal antibody, demonstrated longer median overall survival (7.5 vs. 5.1 months) and improved response (13.3% vs. 5.8%) versus investigator choice chemotherapy (ICC) in patients with rec
Autor:
Kevin J. Harrington, Cathy McDowell, Martin Forster, Jonathan Teague, Paul Gougis, Sharon Forsyth, David Leader, Sandy Beare, Helen Baines, Teresa Guerrero Urbano, Andre Lopes, John A. Hartley, Leah Ensell, R. Mendes, Sola Adeleke, Victoria J. Spanswick
Publikováno v:
Journal of Clinical Oncology. 34:TPS6108-TPS6108
TPS6108Background: Standard care for locally advanced squamous cell carcinoma of the head and neck (HNSCC) is cisplatin-based chemoradiotherapy (C-CRT). Use of intensity modulated radiotherapy (IMR...
Autor:
Stefan Kasper, Justin Kopit, Francis P. Worden, Caroline Even, Manish Monga, James W. Shaw, Jérôme Fayette, A. Dimitrios Colevas, Kevin J. Harrington, Naomi Kiyota, Robert L. Ferris, George R. Blumenschein, William J. Geese, Lisa Licitra, Maura L. Gillison, Joël Guigay, Robert I. Haddad, Everett E. Vokes, Mark Lynch, Makoto Tahara
Publikováno v:
Journal of Clinical Oncology. 34:6009-6009
6009Background: Patients (pts) with R/M SCCHN have poor prognosis, and median OS for pts with platinum-refractory disease is ≤6 mo. We investigated if nivo, a fully human IgG4 anti-PD-1 mAb improve...
Autor:
K. Mettinger, Kevin J. Harrington, George M. Gill, M. Coffey, Eleni M. Karapanagiotou, Hardev Pandha, John D. Chester
Publikováno v:
Journal of Clinical Oncology. 28:3080-3080
3080 Background: Reolysin is an isolate of reovirus, a RNA virus which replicates in cells with activated Ras signaling pathway while sparing normal cells. We conducted a phase I/II dose escalation...